The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL (Q71067297)
Jump to navigation
Jump to search
scientific article published on 01 August 1995
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL |
scientific article published on 01 August 1995 |
Statements
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2 (English)
J C Yang
S L Topalian
D J Schwartzentruber
D R Parkinson
F M Marincola
J S Weber
C A Seipp
D E White
S A Rosenberg
1 August 1995